Toll-like receptor 4 (TLR4) and phosphorylated signal transducer and activator of transcription protein 3 (pSTAT3) play a prominent role in cancer inflammation and anti-tumor immune response, and their therapeutic targeting is considered a promising strategy for the management of breast cancer (BC). This evidence concerns the gene TLR4 and breast cancer.